- Home
- CWD vs TOVX Comparison
CWD vs TOVX Comparison
Compare CWD & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWD
- TOVX
- Stock Information
- Founded
- CWD 2009
- TOVX 2001
- Country
- CWD United States
- TOVX United States
- Employees
- CWD N/A
- TOVX N/A
- Industry
- CWD Real Estate
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- CWD Finance
- TOVX Health Care
- Exchange
- CWD Nasdaq
- TOVX Nasdaq
- Market Cap
- CWD 4.5M
- TOVX 3.8M
- IPO Year
- CWD 2023
- TOVX 2006
- Fundamental
- Price
- CWD $3.39
- TOVX $0.50
- Analyst Decision
- CWD
- TOVX Hold
- Analyst Count
- CWD 0
- TOVX 1
- Target Price
- CWD N/A
- TOVX N/A
- AVG Volume (30 Days)
- CWD 23.9K
- TOVX 183.1K
- Earning Date
- CWD 08-11-2025
- TOVX 08-12-2025
- Dividend Yield
- CWD N/A
- TOVX N/A
- EPS Growth
- CWD N/A
- TOVX N/A
- EPS
- CWD N/A
- TOVX N/A
- Revenue
- CWD $35,429,000.00
- TOVX N/A
- Revenue This Year
- CWD N/A
- TOVX N/A
- Revenue Next Year
- CWD $31.12
- TOVX N/A
- P/E Ratio
- CWD N/A
- TOVX N/A
- Revenue Growth
- CWD N/A
- TOVX N/A
- 52 Week Low
- CWD $3.00
- TOVX $0.40
- 52 Week High
- CWD $16.96
- TOVX $7.37
- Technical
- Relative Strength Index (RSI)
- CWD 48.36
- TOVX 45.57
- Support Level
- CWD $3.13
- TOVX $0.42
- Resistance Level
- CWD $3.75
- TOVX $0.48
- Average True Range (ATR)
- CWD 0.30
- TOVX 0.03
- MACD
- CWD 0.05
- TOVX 0.02
- Stochastic Oscillator
- CWD 53.25
- TOVX 88.67
About CWD CaliberCos Inc.
CaliberCos Inc is an asset management firm whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. The majority of revenue is derived from the fund management fees segment.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.